QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
NASDAQ:KRON

Kronos Bio (KRON) Stock Forecast, Price & News

$3.55
-0.21 (-5.59%)
(As of 05/19/2022 04:00 PM ET)
Add
Compare
Today's Range
$3.50
$4.03
50-Day Range
$3.55
$8.42
52-Week Range
$3.50
$28.42
Volume
3.33 million shs
Average Volume
347,157 shs
Market Capitalization
$201.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.94
30 days | 90 days | 365 days | Advanced Chart
Receive KRON News and Ratings via Email

Sign-up to receive the latest news and ratings for Kronos Bio and its competitors with MarketBeat's FREE daily newsletter.

Kronos Bio logo

About Kronos Bio

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRON
Fax
N/A
Employees
96
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$5.59 per share

Profitability

Net Income
$-151.08 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
39,032,000
Market Cap
$201.40 million
Optionable
Not Optionable

Company Calendar

Last Earnings
2/24/2022
Today
5/19/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.70 out of 5 stars

Medical Sector

222nd out of 1,418 stocks

Pharmaceutical Preparations Industry

83rd out of 677 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -













Kronos Bio (NASDAQ:KRON) Frequently Asked Questions

Is Kronos Bio a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kronos Bio in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Kronos Bio stock.
View analyst ratings for Kronos Bio
or view top-rated stocks.

When is Kronos Bio's next earnings date?

Kronos Bio is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Kronos Bio
.

How were Kronos Bio's earnings last quarter?

Kronos Bio, Inc. (NASDAQ:KRON) announced its earnings results on Thursday, February, 24th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.07) by $0.06.
View Kronos Bio's earnings history
.

What price target have analysts set for KRON?

3 equities research analysts have issued twelve-month price objectives for Kronos Bio's stock. Their forecasts range from $30.00 to $36.00. On average, they expect Kronos Bio's share price to reach $33.00 in the next year. This suggests a possible upside of 829.6% from the stock's current price.
View analysts' price targets for Kronos Bio
or view top-rated stocks among Wall Street analysts.

Who are Kronos Bio's key executives?
Kronos Bio's management team includes the following people:
  • Dr. Norbert W. Bischofberger Ph.D., Pres, CEO & Director (Age 66, Pay $596.37k) (LinkedIn Profile)
  • Mr. Joshua A. Kazam, Co-Founder & Director (Age 45, Pay $35k)
  • Dr. Yasir B. Al-Wakeel BCh, BM, MA, CFO & Head of Corp. Devel. (Age 40, Pay $421.26k)
  • Dr. Jorge F. DiMartino M.D., Ph.D., Chief Medical Officer & Exec. VP of Clinical Devel. (Age 58, Pay $765.11k)
  • Ms. Barbara A. Kosacz J.D., COO, Sec. & Gen. Counsel (Age 64)
  • Dr. Christopher Dinsmore Ph.D., Chief Scientific Officer (Age 56) (LinkedIn Profile)
  • Stephanie Yao, Exec. Director of Investor Relations & Corp. Communications
  • Ms. Marni Kottle, Sr. VP of Corp. Communications & Investor Relations
  • Dr. Pasit Phiasivongsa Ph.D., Sr. VP of Pharmaceutical Devel.
  • Mr. Charles Lin Ph.D., Sr. VP of Biology
When did Kronos Bio IPO?

(KRON) raised $175 million in an IPO on Friday, October 9th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO.

What is Kronos Bio's stock symbol?

Kronos Bio trades on the NASDAQ under the ticker symbol "KRON."

Who are Kronos Bio's major shareholders?

Kronos Bio's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.00%), Capital World Investors (5.43%), Vanguard Group Inc. (4.59%), JPMorgan Chase & Co. (4.52%), State Street Corp (3.40%) and Ensign Peak Advisors Inc (0.78%). Company insiders that own Kronos Bio stock include Backer Marianne De, Barbara Kosacz, Christopher Dinsmore, Elena Ridloff, Fund V LP Omega, Jakob Loven, Jorge Dimartino and Norbert W Bischofberger.
View institutional ownership trends for Kronos Bio
.

Which major investors are selling Kronos Bio stock?

KRON stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Vanguard Group Inc., Woodline Partners LP, Capital World Investors, SG Americas Securities LLC, Citigroup Inc., TD Asset Management Inc., and Ensign Peak Advisors Inc. Company insiders that have sold Kronos Bio company stock in the last year include Christopher Dinsmore, and Jorge Dimartino.
View insider buying and selling activity for Kronos Bio
or view top insider-selling stocks.

Which major investors are buying Kronos Bio stock?

KRON stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., State Street Corp, Renaissance Technologies LLC, IndexIQ Advisors LLC, UBS Group AG, Invesco Ltd., GSA Capital Partners LLP, and Goldman Sachs Group Inc.. Company insiders that have bought Kronos Bio stock in the last two years include Backer Marianne De, Barbara Kosacz, Elena Ridloff, Fund V LP Omega, and Norbert W Bischofberger.
View insider buying and selling activity for Kronos Bio
or or view top insider-buying stocks.

How do I buy shares of Kronos Bio?

Shares of KRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kronos Bio's stock price today?

One share of KRON stock can currently be purchased for approximately $3.55.

How much money does Kronos Bio make?

Kronos Bio has a market capitalization of $201.40 million. The company earns $-151.08 million in net income (profit) each year or ($2.92) on an earnings per share basis.

How many employees does Kronos Bio have?

Kronos Bio employs 96 workers across the globe.

What is Kronos Bio's official website?

The official website for Kronos Bio is kronosbio.com.

How can I contact Kronos Bio?

The company can be reached via phone at 650-781-5200 or via email at [email protected].

This page was last updated on 5/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.